CSPC Pharma taps R&D superstar in quest for new breakout drugs
Liu Yongjun’s drug commercialization experience and ties to multinational firms are urgently needed for his new employer’s ongoing transformation Key Takeaways: CSPC Pharma’s new R&D head Liu Yongjun engineered the…
Stock disconnect triggers investor exodus from CStone Pharma
The share price fell nearly 40% in a week after the drugs company was dropped from a scheme allowing mainland investors to trade Hong Kong-listed stocks Key Takeaways: CEO Jason…
HBM gets health boost from drug licensing deals
The biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer Key Takeaways: Nona Biosciences, a subsidiary of…
FAST NEWS: CStone licenses PD-1 cancer drug to 3SBio for China
The latest: CStone Pharmaceuticals (2616.HK) announced Wednesday that it has exclusively licensed Shenyang Sunshine Pharmaceutical, a subsidiary of 3SBio Inc. (1530.HK), to develop, register, manufacture and commercialize its anti-PD-1 antibody Nofazinlimab…
FAST NEWS: CStone says CEO to boost company holdings
The latest: CStone Pharmaceuticals (2616.HK) on Tuesday announced that its CEO Jason Yang plans to buy up to HK$5 million ($640,000) worth of the company’s shares in the open market over the…
CStone breaks up with drugs partner as U.S. rollout stalls
CStone Pharmaceuticals has pulled out of a licensing deal with EQRx for two innovative cancer drugs but holds onto money already received from its partner Key Takeaways: The companies parted…
FAST NEWS: CStone Raises $50 Million in New Share Placement
The latest: CStone Pharmaceuticals (2616.HK) on Wednesday announced it placed 84.8 million new shares at a price of HK$4.633 per share, raising approximately HK$393 million ($50.4 million). The sale price…
Recent Articles
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK -
Hengrui Pharma accelerates bid for global brand status
600276.SHG
-
Innovent ditches low-value stake sale after investor outcry
1801.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
